NASDAQ · AXSM
Axsome Therapeutics, Inc.
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
Loading market information…
OTC · BTAX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biostax Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biostax Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
$11.75+$0.47 (+4.17%)
ADMA Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.57% below the high.
$1.86-$0.03 (-1.59%)
Polaryx Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.2% below the high.
$1.53+$0.15 (+10.87%)
Actinium Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
$0.73-$0.09 (-11.32%)
Estrella Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.87% below the high.
CA$0.35CA$0.00 (0.0%)
Defence Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$1.22-$0.02 (-1.61%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
$0.02+$0.00 (+17.65%)
Oncotelic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.82% below the high.
